Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
3(75.0%)
Phase 4
1(25.0%)
4Total
N/A(3)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05391074Not ApplicableUnknown

Oral Postbiotics in Patients With Macular Atrophy

Role: lead

NCT05056025Not ApplicableUnknown

Study to Evaluate the Response to Supplementation With Postbiotics in Patients With Macular Degeneration.

Role: lead

NCT01799564Not ApplicableCompleted

Micropulse Laser for Geographic Atrophy

Role: lead

NCT01694095Completed

Evolution and Risk Factors Associated With Geographic Atrophy Progression

Role: lead

NCT01500915Phase 4Completed

FUSION Regimen: Combined Pro re Nata and Fixed Regimen Ranibizumab in Exudative Age-related Macular Degeneration

Role: lead

All 5 trials loaded